Quantifying Adverse Drug Events: Are Systematic Reviews the Answer?

Author： Mahyar Etminan   Bruce Carleton   Paula A. Rochon  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.27, Iss.11, 2004-01, pp. : 757-761

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rosiglitazone and MI risk - will we ever know the answer?

By  

Inpharma, Vol. 1, Iss. 1594, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Pharmacotherapy Crisis in the Spotlight—Is Open Collaboration Between Academia and Industry the Answer?

By Kaski Juan-Carlos  

Cardiovascular Drugs and Therapy, Vol. 25, Iss. 2, 2011-04 ,pp. : 187-188

Springer Publishing Company

Access to resources Recommend Favorite

Management of Hyperglycaemia After Pancreas Transplantation: Are New Immunosuppressants the Answer?

By Francesca M. Egidi  

Drugs, Vol. 65, Iss. 2, 2005-01 ,pp. : 153-166

Adis International

Access to resources Recommend Favorite

NSAID-Related Psychiatric Adverse Events: Who is at Risk?

By Graziano Onder   Francesca Pellicciotti   Giovanni Gambassi   Roberto Bernabei  

Drugs, Vol. 64, Iss. 23, 2004-01 ,pp. : 2619-2627

Adis International

Access to resources Recommend Favorite

SSRI-related adverse events costly?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 337, 2001-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite